We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BEVESPI AEROSPHERE (AstraZeneca Pty Ltd)
Product name
BEVESPI AEROSPHERE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
228 working days (255)
Active ingredients
glycopyrronium bromide (glycopyrrolate); formoterol (eformoterol) fumarate dihydrate
Registration type
EOI
Indication
New combination
BEVESPI AEROSPHERE (inhaler) is indicated as a long-term twice-daily maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).